Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Note: The words woman/women/mother/she/her have been used throughout this guideline as most pregnant and birthing people identify with their birth sex. However, for the purpose of this guideline, these terms include people who do not identify as women or mothers, including those with a non-binary identity. All clinicians should ask the pregnant person what their preferred term is and ensure this is communicated to the healthcare team.

Explanation of the Aboriginal artwork:
The Aboriginal artwork used symbolises the connection to country and the circle shape shows the strong relationships amongst families and the Aboriginal culture. The horseshoe shape design shown in front of the generic statement symbolises a woman and those enclosing a smaller horse shoe shape depicts a pregnant woman. The smaller horse shoe shape in this instance represents the unborn child.

The artwork shown before the specific statements within the document symbolises a footprint and demonstrates the need to move forward together in unison.

Australian Aboriginal Culture is the oldest living culture in the world yet Aboriginal people continue to experience the poorest health outcomes when compared to non-Aboriginal Australians. In South Australia, Aboriginal women are 2-5 times more likely to die in childbirth and their babies are 2-3 times more likely to be of low birth weight. The accumulative effects of stress, low socio economic status, exposure to violence, historical trauma, culturally unsafe and discriminatory health services and health systems are all major contributors to the disparities in Aboriginal maternal and birthing outcomes. Despite these unacceptable statistics the birth of an Aboriginal baby is a celebration of life and an important cultural event bringing family together in celebration, obligation and responsibility. The diversity between Aboriginal cultures, language and practices differ greatly and so it is imperative that perinatal services prepare to respectfully manage Aboriginal protocol and provide a culturally positive health care experience for Aboriginal people to ensure the best maternal, neonatal and child health outcomes.

Purpose and Scope of Perinatal Practice Guideline (PPG)

The purpose of this guideline is to provide clinicians with information for the assessment and management of neonatal abstinence syndrome. It includes use of the Modified Finnegan Neonatal Abstinence Severity (MFNASS) scoring system, non-pharmacological/supportive measures and pharmacological intervention for babies of both opioid and non-opioid dependent mothers.
South Australian Perinatal Practice Guideline

Neonatal Abstinence Syndrome

Flowchart: Management of babies born to an opioid dependent mother

**AT BIRTH**
- Naloxone NOT to be used in resuscitation
- Plan to manage the baby on the postnatal ward, unless there is a separate medical or social indication for admission to a neonatal nursery
- Where birth has occurred at a Level 3 service, seek phone advice from a paediatrician or neonatologist regarding a planned transfer of mother and baby to a Level 4, 5 or 6 service
- Notify the social worker as soon as practical

**POSTNATAL WARD**
- Breastfeeding is encouraged unless the mother is HIV positive. Guidelines regarding the safety of maternal medication for the infant should be consulted on a case by case basis
- Encourage parent involvement in baby’s care
- Commence Modified Finnegan Chart scoring every 4 hours if there are significant signs and symptoms of withdrawal
- Normal Postnatal Ward observations are otherwise performed
- Collect urine for toxicology screen after discussion with paediatrician/neonatologist and parents
- Daily medical assessment and discussion with a paediatrician/neonatologist
- Where appropriate, notification to Social Work and Department of Child Protection
- Commence Modified Finnegan scoring and seek paediatrician/neonatologist advice regarding admission to neonatal nursery if symptoms consistent with drug withdrawal become more evident
- Admit to a Level 4, 5 or 6 nursery if a child safety issue is identified or symptoms develop consistent with drug related encephalopathy (Modified Finnegan Score ≥5 for 3 consecutive scores or ≥12 at any time)
- If in regional setting, consider contacting the Perinatal Advice Line (ph: 137827) for advice
  - Fentanyl withdrawal symptoms
  - Patient should be monitored for at least 5 days; however early discharge for well baby is at consultant discretion

**SPECIAL CARE NURSERY**
- Consider and exclude where appropriate other differential diagnoses:
  - Hypoglycaemia, sepsis, intracranial haemorrhage, hypoxic-ischaemic encephalopathy, withdrawal/interoception from non-opioid medications
  - A urine toxicology screen is performed if not previously obtained with parental consent
- Provide supportive measures/non-pharmacological intervention
- Morphine treatment usually commenced if the modified Finnegan score ≥6 for three assessments or ≥12 for one assessment, including the Postnatal Ward scores. (Discuss dosage with paediatrician/neonatologist, as below)
- Commence cardiorespiratory monitoring when morphine is commenced. Monitoring is required for morphine >0.125mg/kg/dose, and may be ceased when on a stable dose
- Prescribe dose in milligrams not mililitres. Use birth weight for all calculations

<table>
<thead>
<tr>
<th>Modified Finnegan Neonatal Abstinence Severity (MPNAS) scoring</th>
<th>Morphine Dosage (orally)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 8</td>
<td>Non-pharmacological treatment and medical review</td>
</tr>
<tr>
<td>≥ 5 for three consecutive scores OR ≥ 12 for one score</td>
<td>Prescribe stat doses of morphine 0.1mg/kg/dose as needed (minimum interval 4-6 hourly, up to 3 doses in 24 hours). Patient who has received stat doses of morphine should be observed in the hospital for a further 45-72 hours after completion of morphine (observe in nursery for 24 hours, and later in postnatal). Discharge criteria as per prescribed protocol</td>
</tr>
<tr>
<td>Score ≥ 8 despite three stat doses in 24 hours</td>
<td>Commence Morphine 0.1mg/kg/dose, 6 hourly</td>
</tr>
<tr>
<td>Score ≥ 8 despite 0.1mg/kg/dose, 6 hourly</td>
<td>Commence Morphine 0.125mg/kg/dose, 6 hourly</td>
</tr>
<tr>
<td>Score ≥ 8 despite 0.125mg/kg/dose, 6 hourly</td>
<td>Commence Morphine 0.175mg/kg/dose, 6 hourly</td>
</tr>
<tr>
<td>Score ≥ 8 despite 0.175mg/kg/dose</td>
<td>Morphine 0.225mg/kg/dose, 6 hourly</td>
</tr>
</tbody>
</table>

If the infant vomits within 10 minutes of the dose, the dose is repeated. If the infant vomits after 10 minutes, give half the dose again. If the infant vomits 20 minutes after the feed, do not give further morphine
- Maintain control (NAS score <8) for 24-48 hours. Then decrease each dose by 0.05mg/dose every 24-48 hours
- Where control is difficult, give the total daily dose in 6 divided doses (step down doses may then need to be <0.05mg/dose)
- Consider adding Phenobarbital if morphine dose is ≥0.225mg/kg/dose and symptoms are not controlled. or if there is maternal poly-drug use (see Flow Chart for Non-opioid NAS)
- When the dose reaches 0.2mg/dose for 48 hours, consider restart with the previous dose

**DISCHARGE CHECKLIST**
- Infant is feeding well with satisfactory weight gain
- Morphine dose must not exceed 0.2 mg per dose 6 hourly
- Parent education about NAS, routine newborn care, emphasizing safe sleep and SIDS/SUDB risk
- Parent education on basic CPR
- Multi-disciplinary assessment and planning for child safety, coordinating with Department of Child Protection as appropriate
- Safety assessment for staff visiting at home
- Follow-up plan in place: GP, Paediatrician if required, home visiting midwife or neonatal outreach, Child and Family Health
Flowchart: Management of babies born to non-opioid dependent mother

**Baby born to a mother who is dependent on or has regularly used non-opioid drugs including CNS stimulants**

**AT BIRTH**
- **Naloxone NOT** to be used in resuscitation
- Plan to manage the baby on the postnatal ward, unless there is a separate medical or social indication for admission to a neonatal nursery
- Notify the social worker as soon as practical

**POSTNATAL WARD**
- Breastfeeding is encouraged unless the mother is HIV-positive. Guidelines regarding the safety of maternal medication for the infant should be consulted on a case by case basis
- Early discharge should be discouraged
- Encourage parent involvement in baby’s care
- Commence Modified Finnegan chart scoring every 4 hours if there are significant signs and symptoms of withdrawal
- Normal Postnatal Ward observations are otherwise performed
- Collect urine for toxicology screen after discussion with paediatric or neonatologist and parents
- Daily medical assessment and discussion with a paediatric or neonatologist
- Where appropriate, notification to Social Work and Department of Child Protection
- Commence Modified Finnegan scoring and seek paediatric or neonatologist advice regarding admission to neonatal nursery if symptoms consistent with drug withdrawal become more evident
- Admit to a Level 4, 5 or 6 nursery if a child safety issue is identified or symptoms develop consistent with drug related encephalopathy
- If in regional setting, consider contacting the Perinatal Advice Line (ph: 137927) for advice +/- retrieval for babies with significant withdrawal symptoms

**SPECIAL CARE NURSERY**
- Consider and exclude where appropriate other differential diagnoses:
  - Hypoglycaemia, asphyxia, intracranial haemorrhage, hypovolaemic, metabolic, neurological, withdrawal from non-opioid medications
  - A urine toxicology screen is performed if not previously obtained with parental consent
- Provide supportive measures / non-pharmacological intervention
- If baby exhibits symptoms of withdrawal, consider modified Finnegan scoring 4 hourly, until the baby’s symptoms have resolved or a stable dose of phenobarbitaline is attained. If stable on medication, scoring can be 8 hourly
- Phenobarbitaline is the drug of choice for significant non-opioid withdrawal
- Commence phenobarbitaline, if modified Finnegan score > 8 for three assessments or ≥ 12 at any time
- Consider cardiorespiratory monitoring when phenobarbitaline is commenced
- Prescribe dose in milligrams not millilitres. Use birth weight for all calculations

<table>
<thead>
<tr>
<th>Modified Finnegan Neonatal Abstinence Severity (MFNAS) score</th>
<th>Phenobarbitaline Dosage (usually)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 8</td>
<td>Loading dose: 15 mg/kg oral then 2.5 mg/kg/dose BD, reducing 12 hours after loading dose to maintenance</td>
</tr>
<tr>
<td>≥ 8 despite 2.5 mg/kg/dose BD</td>
<td>Increase to 4 mg/kg/dose BD</td>
</tr>
<tr>
<td>≥ 8 despite 4 mg/kg/dose BD</td>
<td>Increase to 5 mg/kg/dose BD</td>
</tr>
</tbody>
</table>

- After scores fall below the treatment level for 24-48 hours, the dose should be reduced by 10%-20% from the previous dose

**DISCHARGE CHECKLIST**
- Infant is feeding well with satisfactory weight gain
- Parent education about NAS, routine newborn care, emphasising safe sleep and SIDS/SUDDI risk
- Parent education on basic CPR
- Multi-disciplinary assessment and planning for child safety, coordinating with Department of Child Protection as appropriate
- Safety assessment for staff visiting at home
- Follow-up plan in place, GP, paediatrician if required, home visiting midwife or neonatal Outreach, Child and Family Health
Flowchart: MFNASS scoring frequency

Commence Modified Finnegan Neonatal Abstinence Severity (MFNASS) scoring if there are any signs of withdrawal.

Assess MFNASS score

- Score < 8
  - Continue scoring at 4 hourly intervals
    - Scores remains < 8
      - Consider reducing scoring to 6-8 hourly until day 3-5
        - If scores < 4, consider ceasing scoring
    - Score ≥ 8 but < 12
      - 1 or 2 times
      - Contact medical team for assessment and admission to level 4, 5 or 6 nursery

- Score ≥ 8 but < 12
  - 3 consecutive intervals
  - OR ≥ 12 once

- Score ≥ 12
  - Contact medical team for assessment and admission to level 4, 5 or 6 nursery
Table of Contents

Purpose and Scope of Perinatal Practice Guideline (PPG) ................................................................. 1
Flowchart: Management of babies born to an opioid dependent mother ................................................. 2
Flowchart: Management of babies born to non-opioid dependent mother ............................................... 3
Flowchart: MFNASS scoring frequency .................................................................................................. 4
Table of Contents .................................................................................................................................... 5
Summary of Practice Recommendations .................................................................................................. 6
Definition .................................................................................................................................................. 6
Abbreviations ........................................................................................................................................... 6
Introduction ................................................................................................................................................ 7
  Associations with maternal use of drugs ................................................................................................. 7
  Antenatal care planning ......................................................................................................................... 7
  Non-Opioid Agents and Presentation ...................................................................................................... 8
Early management after birth .................................................................................................................. 9
Diagnosis of NAS ..................................................................................................................................... 10
Non - Pharmacological Intervention ....................................................................................................... 10
  Environmental control ............................................................................................................................ 10
  Feeding strategies .................................................................................................................................. 10
  Functioning of the mother-infant dyad: ................................................................................................. 11
Pharmacological Intervention .................................................................................................................. 11
  Opioid Withdrawal – Morphine treatment ............................................................................................... 11
    Vomiting in association with morphine dosing: ................................................................................... 12
  Regulation of the prescription of morphine syrup ................................................................................... 12
  Non-Opioid Withdrawal – Phenobarbitone Treatment .......................................................................... 13
Discharge Criteria ..................................................................................................................................... 14
Follow up .................................................................................................................................................. 14
References ................................................................................................................................................ 15
Appendices ................................................................................................................................................. 17
  APPENDIX 1. Modified Finnegan NAS chart ......................................................................................... 17
    Modified Finnegan withdrawal score ...................................................................................................... 17
    Neonatal abstinence syndrome (NAS) scoring chart ............................................................................ 18
  Instructions for scoring using the MFNASS ............................................................................................ 18
  APPENDIX 2. NAS symptoms and suggested techniques ..................................................................... 20
Acknowledgements ..................................................................................................................................... 21
  Write Group Lead ................................................................................................................................... 21
  Write Group Members ............................................................................................................................ 21
  Other major contributors ....................................................................................................................... 21
  SAPPG Management Group Members ................................................................................................ 21
Document Ownership & History .............................................................................................................. 22
Summary of Practice Recommendations

1. Most infants with signs and symptoms of neonatal abstinence syndrome do not require medication.
2. Optimise non-pharmacological intervention first with parental involvement/support.
3. If medication is to be commenced, consider PRN or “as needed” dosing and re-evaluate.
4. Wean regular doses as quickly as possible (e.g., consider daily weaning of medication).

Definition

| Neonatal abstinence syndrome (NAS) | A constellation of signs and symptoms of drug withdrawal in infants after birth. Other terms include opioid withdrawal syndrome or neonatal withdrawal syndrome. |

Abbreviations

| BD       | 12 hourly                      |
| CPR      | Cardiopulmonary resuscitation |
| CAFHS    | Child and Family Health Service |
| DASSA    | Drug and Alcohol Services South Australia |
| DDU      | Drugs of dependence unit     |
| e.g.     | For example                   |
| GP       | General practitioner          |
| HIV      | Human immunodeficiency virus  |
| kg       | Kilogram(s)                   |
| mg       | Milligram(s)                  |
| MFNASS   | Modified Finnegan Neonatal Abstinence Severity Score |
| NAS      | Neonatal abstinence syndrome  |
| NNP      | Neonatal nurse practitioner   |
| NHMRC    | National Health and Medical Research Council |
| %        | Percent                       |
| PPG      | Perinatal Practice Guideline(s) |
| SA       | South Australia               |
| SIDS     | Sudden infant death syndrome  |
| SNRIs    | Serotonin and noradrenaline reuptake inhibitors |
| SSRIs    | Selective serotonin reuptake inhibitors |
| SUDI     | Sudden unexpected death in infancy |
Introduction

Signs and symptoms of NAS can involve the central nervous system (irritability, increased muscle tone, tremors, high pitched cry, and disturbed sleep), can be autonomic (sneezing, fever, yawning, sweating, mottling) and can include the gastrointestinal system (disorganised sucking, vomiting, loose/watery stools or hyperphagia).

Withdrawal symptoms occur as a result of variety of drugs such as opiates, stimulant and antidepressant medications. The onset of withdrawal varies and is dependent on the drug, dose, half-life, gestational age of the infant, and when the drug was last consumed.

The incidence of NAS in Australia has decreased and is estimated to be 3 per 1000 live births.\(^1\)

Not all women will divulge their drug use to health practitioners, partners or relatives. If an infant has symptoms consistent with opioid withdrawal, a history should be taken from the mother in a sensitive manner and in a private setting.\(^2\)

Infants suspected of opioid withdrawal should be examined thoroughly and other possible causes excluded.

Care planning (including screening, treatment and management) should be family centered, individualised with frequent evaluation.

Associations with maternal use of drugs

More than 50% of maternal drug use have co-existing psychiatric morbidity\(^3\); most commonly depression

Whilst there is no documented increase in congenital abnormalities in infants of opiate, marijuana using mother, infants born to mothers using illicit drugs are also at risk of adverse neonatal outcomes such as growth restriction, birth defects, sudden infant death and preterm birth\(^4,5\)

There is no increase in fetal abnormality in mothers who use opioids, amphetamines, or marijuana

Antenatal care planning

If a woman is known to be dependent on opioid or non-opioid substances during pregnancy, a multidisciplinary team meeting should be arranged for around 32 weeks gestation to undertake an assessment of risk to the unborn child and to develop a family support plan. The woman and her partner, maternity care providers (obstetrician, GP, midwife, AMIC worker), Drug and Alcohol Services South Australia (DASSA) clinician (if relevant), neonatologist/paediatrician, hospital social worker/case coordinator and local Department for Child Protection (DCP) case manager (if allocated), should be involved in this team meeting.
# Non-Opioid Agents and Presentation

<table>
<thead>
<tr>
<th>Agent</th>
<th>Presentation</th>
<th>Management considerations</th>
</tr>
</thead>
</table>
| Amphetamine/ Methamphetamines | Lethargy, somnolence and poor feeding                                        | The majority of amphetamine-exposed infants require only minimal supportive treatment. Few require pharmacological treatment Avoid early discharge after birth Ensure:  
> Early discharge planning and referral to relevant community support agencies  
> Psychosocial assessment and liaison with child safety services prior to discharge  
> Provide midwifery support with particular emphasis on breastfeeding support and parenting skills  
> Family and social supports are in place  
> Paediatric team are involved in neonate’s hospital discharge and follow-up |
| SSRI/SNRIs (antidepressant medication) | Symptoms are usually mild and most develop within 48 hours of birth and resolve without treatment within two to six days. They include:  
> Increased muscle tone  
> Mild or marked tremors while undisturbed  
> Exaggerated Moro reflex (i.e. startle)  
> Loose or watery stools  
> Poor feeding  
> Poor sleep (less than 1-2 hours sleep after feeding)  
> Poor feeding | Avoid early discharge after birth  
Non-pharmacological measures to support infant through withdrawal  
Breastfeeding encouraged |
| Cocaine                       | Autonomic stability  
Jitteriness  
Irritability/ high pitched cry  
Excessive sucking and agitation | Avoid early discharge after birth  
Non-pharmacological measures to support infant through withdrawal |
| Alcohol                       | > Jitteriness  
> Irritability  
> Poor feeding  
> At modest risk of hypoglycemia  
> Seizure (rare) | Avoid early discharge after birth  
Non-pharmacological measures to support infant through withdrawal |
Early management after birth

- **DO NOT give Naloxone** in resuscitation of babies born to opioid dependent mothers as it has the potential to cause life-threatening withdrawal symptoms including seizures.
- Ineffective breathing or apnoea in the newborn is managed by positive pressure ventilation in accordance to Australian Resuscitation Council guidelines.
- Urine toxicology screening is useful to determine which drugs the infant has been recently exposed to in utero where this is unclear from maternal history. Verbal consent for the urine toxicology screen is required and consent should be documented in the Medical Record. The test should not be taken if parental consent is not obtained, unless there is a legal directive to do so.
- If the infant is otherwise well with no child safety issues are identified, he/she should room in and be observed with mother on the postnatal ward.
- NAS is likely to be more severe in infants that have been exposed to opioid derivatives and multiple substances during antenatal period. The infant should be reviewed daily by a medical officer or neonatal nurse practitioner.
- **DO NOT ROUTINELY** score infants born to maternal opioid dependence using a Neonatal Abstinence Score chart (modified Finnegan chart) unless they are symptomatic.
- The NAS scoring system is a guide and not a precise measure of the infant's clinical course.
- Parents are to be educated with the scoring tool and be encouraged to participate in scoring.
- Encourage breastfeeding or expression of breast milk.
- Daily assessment for withdrawal signs and symptoms, adequacy of feeds and weight gain will enable early recognition and appropriate intervention for the infant.
- Liaise with medical team, social work services and involvement of Department of Child Protection should there be any indication of child-at risk.

| Benzodiazepines | > May be floppy and lethargic  
| > May be jittery with increased tone  
| > Irritability  
| > Poor feeding | > Extended stay with observation for signs of withdrawal  
| > Should have outpatient review in first weeks of life  
| > Educate parents to observe for signs of withdrawal after hospital discharge may be helpful, with instructions to present earlier if indicated by the infant's behaviour  
| > Non-pharmacological measures to support infant through withdrawal  
| > Phenobarbitone may be required |

| Cannabis | Mild withdrawal signs:  
| > Tremors  
| > Exaggerated startle  
| > Lethargy  
| > Poor sleep | > Avoid early discharge after birth  
| > Non-pharmacological measures to support infant through withdrawal  
| > Breast feeding encouraged |
Diagnosis of NAS

> Evaluation of signs of neonatal withdrawal should commence using the Modified Finnegan Neonatal Abstinence Severity Score (MFNASS); the Australian standard designed for assessment of opioid withdrawal in term infants.6-11
> Scoring should occur if signs of withdrawal are evident and then subsequently every 4 hours (see flowchart)
> The Neonatologist or Paediatrician should consider and exclude where appropriate other differential diagnoses (e.g. hypoglycaemia, sepsis, intracranial haemorrhage and hypoxic-ischaemic encephalopathy)
> Urine toxicology may be clinically helpful to determine the source of substance exposure and risk of abstinence (with documented maternal informed consent or a legal directive)
> The MFNASS has only been validated for opioid NAS yet can still be helpful in assessing non-opioid NAS.6,7
> The MFNASS has limited use in the premature infant who may display less signs of withdrawal
> Evaluation and scoring occur every 4 hours. Scoring is based on the infant’s behaviour and symptoms exhibited over the previous 4 hours (see Instructions for scoring using the MFNASS - Appendix 1). This can also be scored in the EMR.
> The clinician should be well educated on the use of the MFNASS and had directly cared for the infant over the previous 4 hours
> Scoring is performed 30 minutes to 1 hour after the infant has been fed by experienced medical staff/midwives/nurses
> Infants with an abstinence score of 8 or more for three consecutive scores or ≥12 at any time should be discussed with a Neonatologist or Paediatrician and the infant transferred to a Level 4, 5 or 6 Special Care Unit for continuous monitoring
> If there are inconsistencies in the scores, the infant may be observed for a period in a level 4, 5 or 6 Special Care Unit to ensure morphine treatment is justified
> It is important that the mother is actively involved in the scoring process to facilitate family participation in care. Staff should discuss each sign as it is assessed with the mother

Non-Pharmacological Intervention

> Most infants with signs and symptoms of abstinence DO NOT REQUIRE medication but respond well with non-pharmacological intervention.
> Non-pharmacological measures are the first-line treatment of NAS and should then be continued as an adjunct to pharmacological treatment. Parents and staff should be educated on these interventions.12-19 (Appendix 2)

Environmental control

> Dimmed room lighting, quiet setting, position and comfort measures (e.g. swaying and rocking, swaddling, non-nutritive sucking, clustered care, bathing, music therapy, massage

Feeding strategies

> Small, frequent feeds, infant-led feeding, breast milk.20
> Encourage establishment and continuation of breastfeeding if the mother is HIV negative and no other contraindications for breastfeeding exist
> Breastfeeding has been demonstrated to significantly reduce NAS symptoms, the need for treatment, treatment duration and length of hospital stay.19
> Provide education to the mother around these benefits of breastfeeding or providing expressed breast milk
Functioning of the mother-infant dyad:

> Fostering parental presence, rooming in, skin to skin contact, direct parental support from clinicians

> Infants should room in with their mothers if it is safe and feasible. Evidence suggests that rooming-in is associated with a decreased need for pharmacological treatment and length of hospital stay\textsuperscript{14}

> Non-judgmental care based on trauma-informed care principles should be provided to mothers to foster maternal involvement and parental well-being\textsuperscript{21}

\*New family-centred model of care for treatment of Neonatal abstinence syndrome (Eat, Sleep, Console Approach) been developed and practiced\textsuperscript{22-26}. This method focuses on maximising non–pharmacological intervention, with encouragement of family involvement and morphine use only as needed.

\*There is growing evidence that this model of care for infants with NAS reduces the length of stay, reduces medication use and is cost effective.\textsuperscript{22} However, the research evidence is still evolving and the efficacy of this novel model has not been rigorously researched.

### Pharmacological Intervention

#### Opioid Withdrawal – Morphine treatment

Only commence after reassessing and maximising non-pharmacological management\textsuperscript{8-11,26-30}

Commence cardiorespiratory monitoring when morphine is prescribed.

<table>
<thead>
<tr>
<th>MFNASS Score</th>
<th>Morphine dosage (oral)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\geq 8$</td>
<td>Non-pharmacological treatment and medical review</td>
</tr>
<tr>
<td>$\geq 8$ for three consecutive scores OR $\geq 12$ for one score</td>
<td>Prescribe stat doses of morphine $0.1\text{mg/kg/dose}$ as needed (minimum interval of 4 hourly, up to 3 doses in 24 hours). Continue non-pharmacological intervention (observe in the nursery for 24 hours)</td>
</tr>
<tr>
<td>Score $\geq 8$ despite three stat doses in 24 hours</td>
<td>Commence Morphine $0.1\text{mg/kg/dose}$ 6 hourly orally</td>
</tr>
<tr>
<td>Score $\geq 8$ despite $0.1\text{mg/kg/dose}$ 6 hourly</td>
<td>Commence Morphine $0.125\text{mg/kg/dose}$ 6 hourly orally</td>
</tr>
<tr>
<td>Score $\geq 8$ despite $0.125\text{mg/kg/dose}$ 6 hourly</td>
<td>Commence Morphine $0.175\text{mg/kg/dose}$ 6 hourly orally</td>
</tr>
<tr>
<td>Score $\geq 8$ despite $0.175\text{mg/kg/dose}$ 6 hourly</td>
<td>Morphine $0.225\text{mg/kg/dose}$ 6 hourly orally</td>
</tr>
</tbody>
</table>

(Calculate to nearest $0.05\text{mg/dose}$)

> Where control is difficult give the total daily dose in 6 divided doses e.g. 4 hourly (step-down doses may then need to be <$0.05\text{mg}$)\textsuperscript{8-10}

> Consider adding adjunct treatment of phenobarbitone if morphine dose is $>0.225\text{mg/kg/dose}$ or if there is maternal poly-drug use\textsuperscript{8-11,31}

> Please note: All doses for the entire period of withdrawal management are calculated on the basis of birth weight and not on current weight

> Once symptoms has been controlled (three consecutive scores of <8), using this

> Dosage regimen, implement the following:

> o Maintain control for 24- 48 hours

> o Initiate the weaning process by decreasing each dose by 0.05mg every 24-48 hours 4 hourly dose may be reduced to 6 hourly

> When dosage levels reach 0.2 mg/dose – maintain this dose for 48 hours. At this dose, consideration can be given to home management

> Discontinue morphine when dose 0.1mg/dose
When oral morphine treatment is discontinued, the NAS scoring should continue for a further 48-72 hours if an inpatient.

**Vomiting in association with morphine dosing:**
- Ensure infant is not being overfed
- Ensure infant is appropriately postured during and after feeding
- Give morphine before the feed

If infant has a large vomit after being given morphine:
- Re-dose if infant vomits within 10 minutes after a dose
- Give ½ dose if infant vomits 10-20 minutes after a dose
- If infant vomits >20 minutes after feed, do not give further morphine

**Regulation of the prescription of morphine syrup**
- The Drugs of Dependence Unit regulates the prescription of morphine for treatment of neonatal abstinence in the context of maternal opioid dependence. The following points should be noted:
  - Authority for prescription of morphine syrup for NAS is restricted to qualified consultants/registrars/NNP.
  - Authority to prescribe requires written application to the Drugs of Dependence Unit (DDU) from the treating paediatrician in the following circumstances:
    - where inpatient therapy exceeds 14 days
    - pre-discharge, where treatment is to be continued in the community for longer than 14 days and inpatient treatment is less than 14 days
    - where treatment is commenced in a private hospital
    - where treatment is continued in a private hospital by a paediatrician other than the authorised paediatrician who commenced treatment in the public hospital
  - Authority is given for the period that the treating specialist requests on the application form. An individual authority with a unique number is required for each new patient.
  - Authority is given subject to the use of morphine syrup in accordance with this Perinatal Practice Guideline or a hospital approved guideline for abstinence treatment.
  - Authority can be obtained irrespective of parental consent, although consent is desirable.
  - Exemptions to the requirement for authority are as follows:
    - where inpatient treatment is less than 14 days AND where treatment on discharge following inpatient treatment does not exceed 14 days
    - where morphine is prescribed as an inpatient or outpatient as part of a pain or palliative care treatment plan, in which circumstances authority is not required for a period of up to 2 months
  - Under the legislation, other paediatricians employed at the same or another public hospital, or a community general practitioner where a paediatrician considers this appropriate, may be a locum prescriber for the authorised prescriber provided this locum:
    - undertakes due care in assessing the infant’s treatment including practicing within approved guidelines and consulting appropriately with a paediatrician
    - complies with the conditions of the authority
    - refers to a paediatrician if three or more consecutive doses of morphine are missed
  - Application forms are available from [SA Health website](#).
  - Once an application is received an authority can be issued (if approved) to the paediatrician/consultant and a copy forwarded to the hospital pharmacist.
Non-Opioid Withdrawal – Phenobarbitone Treatment

- If the mother does not use opioid drugs but uses central nervous system stimulants (amphetamines, cocaine, SSRIs, SNRIs) or depressants (e.g. benzodiazepines and alcohol) the infant is observed for evidence of NAS on the postnatal ward
- The NAS chart is not validated for the assessment of non-opioid withdrawal but can still be of use in clinical decision making
- Neonatal abstinence syndrome is not routinely scored with NAS score chart, but scoring is commenced if the infant exhibits signs consistent with NAS (persistent crying/poor settling following feeds, tremors/jerks/seizures, poor feeding, diarrhoea/vomiting, fever >37.5°C per axilla, tachypnoea, sleepy behaviour)
- The assessment procedures using the NAS chart are as described under opioid NAS
- Babies with NAS score of >8 should be discussed with a neonatologist/paediatrician and consideration given to transferring to a Level 4, 5 or 6 nursery for observation and further management
- Phenobarbitone is the drug of choice for significant non-opioid NAS
- If there are inconsistencies in the scores, the infant may be observed for a period of time in a level 4,5 or 6 nursery to ensure phenobarbitone treatment is truly indicated
- It is important that the mother is actively involved in the scoring process to facilitate ongoing care for the infant. Staff should discuss each sign as it is assessed
- Commencement of phenobarbitone should only occur in a level 4, 5 or 6 nursery with supervision by paediatrician or neonatologist
- Cardiorespiratory or oximetry monitoring is routinely required at the commencement of phenobarbitone as respiratory depression, including apnoeas, may occur following a loading dose
- Where a mother is on a combination of methadone and benzodiazepines and the infant is not settling with morphine treatment alone, the addition of phenobarbitone treatment may be helpful in the management of withdrawal symptoms

<table>
<thead>
<tr>
<th>MFNASS Score</th>
<th>Phenobarbitone dosage (oral)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 8</td>
<td>Loading dose: 15 mg/kg oral then 2.5 mg/kg/dose orally BD commencing 12 hours after loading dose as maintenance</td>
</tr>
<tr>
<td>≥ 8 despite 2.5mg/kg/dose BD</td>
<td>Increase to 4 mg/kg/dose orally BD</td>
</tr>
<tr>
<td>≥ 8 despite 4mg/kg/dose BD</td>
<td>Increase to 5 mg/kg/dose orally BD</td>
</tr>
</tbody>
</table>

After scores fall below treatment level for 24-48 hours, the dose should be reduced by 10%-20% from previous dose.
Discharge Criteria

> Duration of hospitalisation may be tailored according to the type of substance used and other factors such as social circumstances. Infants at risk of NAS caused by opioid withdrawal (including methadone and buprenorphine) and/or benzodiazepine should be monitored in hospital for at least 5 days. Most infants will exhibit signs and symptoms by 72 hours; however, some infants may have a delayed onset if they have been exposed to long–acting substances or prolonged benzodiazepines in utero.

> Earlier discharge for infants who are well (with short exposure of opioids) and has an appropriate safety discharge plans/ follow up could be considered at consultant’s discretion.

> Outpatient management of neonatal abstinence may be considered when morphine doses are <0.2mg/dose AND infant’s symptoms are well controlled with satisfactory weight gain AND families for whom home management is appropriate

> Parents and caregivers are educated on NAS withdrawal symptoms, routine newborn care, basic CPR and instruction regarding administration of medications given to parents.

> Parents and caregivers are provided with information on safe sleeping practices (as according to SA Health - Safe Infant Sleeping Standards) and the risk of SIDS/ SUDI

> Multi-disciplinary planning for safe care has occurred with social worker or coordinating with local Department for Child Protection service as appropriate.

> Rooming in for 24-48 hours is encouraged to assist with assessment of parenting skills, psychological stability and general education and specific instruction regarding administration of medications.

> Follow up plan in place (as below)

> Safety assessment for staff visiting at home has been performed.

Follow up

> General Practitioner review within 2 weeks

> Weekly Paediatrician outpatient review is required for infants discharged on medications for NAS

> Other follow up plans as per multidisciplinary plan: Maternity outreach, Neonatal outreach and Child and Family Health, or Department for Child Protection

> The parents should be counselled regarding the need for hepatitis C screening of their child at 12-18 months where the mother is hepatitis C positive. Referral to paediatric infectious disease specialist if appropriate.
References


### APPENDIX 1. Modified Finnegan NAS chart

**Modified Finnegan withdrawal score**

<table>
<thead>
<tr>
<th>SYSTEM</th>
<th>SIGNS &amp; SYMPTOMS</th>
<th>REASON</th>
<th>NEONATAL WITHDRAWAL SCORING CHART (TERM INFANTS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WARD UNIT NO:</td>
<td>SURNAME, OTHER NAMES:</td>
<td>DOB:</td>
<td>SEX:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CENTRAL NERVOUS SYSTEM DISTURBANCES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>System</td>
<td>Signs &amp; Symptoms</td>
<td>Score</td>
<td></td>
</tr>
<tr>
<td>High-Pitched Cry</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuous High-Pitched Cry</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleeps &lt; 1 hour after feeding</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleeps &lt; 2 hours after feeding</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleeps &lt; 3 hours after feeding</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild tremors when disturbed</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mod-severe tremors when disturbed</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild tremors undisturbed</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mod-severe tremors undisturbed</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased Muscle Tone</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excoriation (specify area)</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myoclonic Jerks</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Generalised Convulsions</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>METABOLIC/MOTOR DISTURBANCES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever (37.3°C – 38.3°C)</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever (38.4°C and higher)</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frequent Yawning (&gt;3-4 times)</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal Stiffness</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sneezing (&gt;3-4 times)</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal Flaring</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory Rate &gt; 60 / min</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory Rate &gt; 60 / min with retractions</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GASTROINTESTINAL DISTURBANCES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excessive sucking</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor Feeding</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regurgitation</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Projectile Vomiting</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loose Stools Watery Stools</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max Score: 41</td>
<td>TOTAL SCORE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCORER’S INITIALS</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Neonatal abstinence syndrome (NAS) scoring chart

Instructions for scoring using the MFNASS

- The score should be based on the infant’s behaviour/symptoms exhibited over the previous 4 hours
- Some scales are of increasing severity and only 1 score should be made for each category
- Modifications for prematurity are mainly necessary in the sections on sleeping, e.g. an infant who needs three-hourly feeds can only sleep at most 2.5 hours between them
- Scoring should be 1 if the infant sleeps less than two, 2 if sleeps less than one hour, and 3 if the infant does not sleep between feeds. Many premature infants require tube feeding
- Infants should not be scored for poor feeding if tube feeding is routine for their gestation

| CNS disturbances | Cry: | If the infant can be consoled and ceases crying within 5 minutes, the score would be 2 for a high-pitched crying. If the infant continues to cry for longer than 5 minutes despite consoling measures, the score would be 3 for continuous crying |
| Metabolic/vasomotor/respiratory disturbances | Sleep: | Scored based on the longest time the infant sleeps without being disturbed |
| Disturbed tremors: | Occurs when the infant is handled. Mild tremors of the hands or feet should score 1, tremors involving the entire arm/leg (moderate/severe) score 2 |
| Undisturbed tremors: | Examined after the infant has been disturbed and has 20 to 30 seconds of being undisturbed. If tremors of the hands or feet continue score 3. Tremors of the entire extremity (moderate/severe) score 4. |
| Increased muscle tone: | Assessed using the pull-to-sit manoeuvre when the infant is not crying. Score if the infant has increased muscle tone; meaning their arms are straight and their body and head are raised without any head lag |
| Excoriation: | Score if excoriation is present during the scoring period |
| Myoclonic jerks: | Involuntary spasms or twitching movements of a muscles in face or extremities, often stimulation induced |
| Generalised convulsions: | Tonic seizures are generalised activity involving tonic extension of all limbs that continue even when the effected limb is touched or flexed |
| Metabolic/vasomotor/respiratory disturbances | Fever: | Ensure sweating or fever is not related to overheating from being overdressed or overwrapped |
| Yawning/sneezing: | yawns or sneezes occurring more than 3 times in the 4-hour scoring interval |
| Nasal stuffiness/flaring: | Flaring occurring during inspiration |
| Respiratory rate: | Count for 1 minute when the infant is not crying |
| Respiratory rate with retractions: | The presence of an indentation of the chest wall during breathing |
### Gastrointestinal disturbances

<table>
<thead>
<tr>
<th><strong>Excessive sucking:</strong></th>
<th>Score if the infant cannot attach properly onto a pacifier or teat whilst turning the head from side to side</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Poor feeding:</strong></td>
<td>Infrequent sucking during the feeding, or taking small amounts of formula or breast milk, or uncoordinated sucking, or prolonged time to complete the feed (&gt;20 minutes)</td>
</tr>
</tbody>
</table>

### Regurgitation and projectile vomiting

<table>
<thead>
<tr>
<th><strong>Regurgitation:</strong></th>
<th>Effortless return of gastric contents from the mouth. Score if frequent (≥2 times) and not associated with burping</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Projectile vomiting:</strong></td>
<td>Ejection of the stomach contents from the mouth under force. Score if 1 or more episodes occur during or after feeding</td>
</tr>
<tr>
<td><strong>Loose stools:</strong></td>
<td>May or may not explosive, curdy or seedy stool</td>
</tr>
<tr>
<td><strong>Watery stools:</strong></td>
<td>Water circulating the stool in a ring</td>
</tr>
</tbody>
</table>

Adapted from: D’Apolito KC. Assessing neonates for neonatal abstinence: are you reliable? The Journal of Perinatal and Neonatal Nursing 2014; 28(3):220-31
## APPENDIX 2. NAS symptoms and suggested techniques

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Techniques</th>
</tr>
</thead>
</table>
| Prolonged and/or high-pitched crying       | • Holding/containment techniques: **Swaddling**: tightly wrap the infant with a light muslin wrap ensuring not to over-heat  
  **Holding**: Hold the infant’s hands against their chest in a supine position, providing firm but gentle pressure to the trunk or head  
  • Handle in a soft, slow manner  
  • Decrease environmental stimulus e.g. decrease loud noises, provide dim lighting  
  • Avoid rocking beds which may increase NAS symptoms and ensure sleep practices are in accordance with safe sleeping guidelines  
  • Pacifiers can have a soothing and state-organising effect |
| Sleeplessness                               | • Decrease environmental stimuli  
  • Cluster care to avoiding unnecessary tactile stimuli  
  • Encourage skin to skin contact  
  • Demand feed |
| Difficult or poor feeding                   | • Provide frequent, small volume, on-demand feeding  
  • Feed in a quiet, calm environment with minimal noise or stimulus  
  • Pause the feed if the infant is becoming tired, needs to reposition or requires self-organisation |
| Regurgitation and/or vomiting               | • To wind, rub the back instead of patting (which may provoke hyperactive Moro reflex in some infants)  
  • Some infants may require a pacifier during winding if they become distressed when the feed is paused |
| Excessive sucking of fists                  | • Cover hands with mittens |
| Hyperactivity                               | • Reduce environmental stimuli including sound and light  
  • Gentle vertical rocking, swaying, swaddling, and containment of hands  
  • Avoid unnecessary tactile stimuli by clustering care and providing skin to skin  
  • Visual stimulation with black and white objects may prevent overstimulation |
| Trembling                                   | • Avoid excessive handling  
  • Gentle handling and containment, positioning, non-nutritive sucking, and swaddling |
| Fever (Temperature over 37°C)               | • Fold a blanket across the chest to contain the arms if they cannot tolerate being wrapped due to fever  
  • Reduce clothing and blankets  
  • Monitor temperature as clinically indicated |
Acknowledgements

The South Australian Perinatal Practice Guidelines gratefully acknowledge the contribution of clinicians and other stakeholders who participated throughout the guideline development process particularly:

Write Group Lead
Dr Alvin Tan

Write Group Members
Dr Michael Hewson
Erin Grace
Kim Gibson
Dr Gillian Watterson

Other major contributors
Emma Marshall

SAPPG Management Group Members
Sonia Angus
Lyn Bastian
Dr Elizabeth Beare
Elizabeth Bennett
Dr Feisal Chenia
John Coomblas
Dr Danielle Crosby
Dr Vanessa Ellison
Dr Ray Farley
Allison Waldron
Dr Kritesh Kumar
Catherine Leggett
Dr Anupam Parange
Rebecca Smith
A/Prof Chris Wilkinson
Document Ownership & History

**Developed by:** SA Maternal, Neonatal & Gynaecology Community of Practice  
**Contact:** HealthCYWHPerinatalProtocol@sa.gov.au  
**Endorsed by:** Domain Custodian, Clinical Governance Safety and Quality  
**Next review due:** 21/02/2027  
**ISBN number:** 978-1-76083-485-2  
**CGSQ reference:** PPG010  
**Policy history:**

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>21/02/2022</td>
<td>V4</td>
<td>Domain Custodian, Clinical Governance Safety and Quality</td>
<td>Formally reviewed.</td>
</tr>
<tr>
<td>23/09/2013</td>
<td>V3</td>
<td>SA Health Safety &amp; Quality Strategic Governance Committee</td>
<td>Formally reviewed in line with scheduled timeline for review</td>
</tr>
<tr>
<td>18/02/2008</td>
<td>V2</td>
<td>SA Health Maternal and Neonatal Clinical Network</td>
<td>Formally reviewed in line with scheduled timeline for review</td>
</tr>
</tbody>
</table>